NCT01507311View on ClinicalTrials.gov

Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 30, 1999

Primary Completion Date

December 31, 1999

Study Completion Date

December 31, 1999

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

liraglutide

A single dose injected subcutaneously (under the skin)

DRUG

placebo

A single dose injected subcutaneously (under the skin)

Trial Locations (1)

8000

Novo Nordisk Investigational Site, Århus C

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY